🎯 Retatrutide Beats Ozempic in First Head-to-Head Trial
Lilly's triple agonist faced the highest approved dose of Ozempic head-on in phase 3 — and delivered more than double the weight loss, with a bigger A1C drop to match.
Eli Lilly has reported topline results from TRANSCEND-T2D-2, the first phase 3 trial to test retatrutide head-to-head against another incretin medicine. The randomized, open-label study enrolled 1,298 adults whose type 2 diabetes was not controlled on metformin, with or without an SGLT2 inhibitor. Participants started with an average A1C of 8.3% and an average weight of 225.8 pounds, and were assigned to once-weekly retatrutide 9 mg, retatrutide 12 mg, or Ozempic (semaglutide) 2 mg — the highest approved Ozempic dose for diabetes — for 80 weeks.
The gap was not close. Both retatrutide doses lowered A1C by 2.2 percentage points, against 1.8 points for Ozempic. On weight, retatrutide pulled away: 19.5% lost at 9 mg and 20.9% at 12 mg — 44.3 and 47.4 pounds — versus 9.4%, or 20.9 pounds, on Ozempic. The trial's primary bar was noninferiority on A1C for the 12 mg dose; retatrutide cleared it and showed superiority on both A1C and weight. It is the sixth phase 3 retatrutide trial to report positive results.
🧩 Three receptors, one weekly shot
GLP-1
Appetite, satiety, and insulin signaling — the pathway Ozempic works alone.
GIP
The second incretin — the metabolic partner tirzepatide added.
Glucagon
Pushes energy expenditure up — the third lever Ozempic doesn't touch.
Retatrutide = GLP-1 + GIP + glucagon, against Ozempic's GLP-1 alone.
📈 The 80-week gap
Weight loss at 80 weeks (%)
Efficacy-estimand results from Lilly's topline release; full datasets have not yet been published.
Why the third receptor matters: GLP-1 and GIP mostly work the intake side of the equation — appetite, satiety, insulin. Glucagon works the other side, raising energy expenditure. That three-way pull is the leading explanation for how a weekly injection in a diabetes population — where weight loss usually runs lower than in obesity-only trials — reached past 20%. Lilly's cardiometabolic president, Kenneth Custer, framed the result in the release:
Tolerability is the counterweight. Gastrointestinal effects were the most common side effects, as across the class. An unusual sensory symptom, dysesthesia, appeared in 4.8% of the 9 mg group and 6.5% of the 12 mg group, versus 2.7% on Ozempic. Discontinuation due to side effects ran 4.8% and 7.9% on retatrutide against 2.7% on Ozempic — the familiar trade: the strongest efficacy in the class, at the price of a harder ride up the dose ladder.
⚖️ Honest caveats
- These are company-presented topline results from a Lilly news release (Oct 28, 2026) — not yet peer-reviewed; detailed results are promised at a future medical meeting and in a journal.
- The trial was open-label and ran in people with type 2 diabetes on metformin — it does not show how retatrutide compares for weight loss in people without diabetes.
- Retatrutide is investigational and is not approved by the FDA or any other regulator.
The next test is the harder one. Beating Ozempic resets the scoreboard against Novo Nordisk, but the field's reigning champion is Lilly's own tirzepatide — and the TRIUMPH-5 trial is already comparing retatrutide against it directly. If the triple agonist wins that one too, the three-receptor era becomes the story of the decade in metabolic medicine.
📚 Sources
- Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial — Eli Lilly news release, October 28, 2026, via AJMC
- TRANSCEND-T2D-2: Retatrutide beats semaglutide 2 mg on A1C, weight loss — HCPLive, October 28, 2026
- Trial record: TRANSCEND-T2D-2, ClinicalTrials.gov NCT06260722 — randomized, open-label, 2:2:1, 80 weeks